Welcome to our dedicated page for Adverum Biotech SEC filings (Ticker: ADVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADVM SEC filings page provides access to the historical regulatory record of Adverum Biotechnologies, Inc., a clinical-stage gene therapy company that focused on ocular diseases such as wet age-related macular degeneration (wet AMD). As a former Nasdaq Capital Market registrant, Adverum filed current reports, financial statements, and transaction documents with the U.S. Securities and Exchange Commission, documenting both its clinical development activities and its corporate evolution, including its acquisition by Eli Lilly and Company.
Among the most informative documents for ADVM are its Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and progress of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec). Investors and researchers can review these filings to understand how Adverum characterized its intravitreal gene therapy platform, the design of pivotal trials such as the Phase 3 ARTEMIS study in wet AMD, and the regulatory designations obtained for Ixo-vec.
Frequent Form 8-K current reports capture material events. For ADVM, these include the October 24, 2025 8-K describing the Agreement and Plan of Merger with Eli Lilly and Company, and the November 21, 2025 8-K noting completion of target enrollment in the ARTEMIS trial and the termination of a North Carolina lease. Earlier 8-Ks furnish press releases on quarterly financial results and pipeline updates, providing additional context on Adverum’s cash runway, clinical milestones, and strategic reviews.
Users can also examine tender offer and merger-related filings referenced in the 8-Ks, which outline the terms of Lilly’s cash offer plus non-tradable contingent value rights (CVRs) for each ADVM share. These documents explain the milestones tied to potential CVR payments and the conditions required to close the transaction. Together, the ADVM filings form a detailed archive of Adverum Biotechnologies’ regulatory history leading up to and including its acquisition, and AI-powered summaries on this page can help distill key points from lengthy reports such as 10-Ks, 10-Qs, and 8-Ks.
Adverum Biotechnologies reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1, and the cover page of the report is presented in Inline XBRL as Exhibit 104.
The filing explicitly states that the information in the report and the exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K itself does not include the underlying financial figures; the detailed results are contained in the furnished press release.
Adverum Biotechnologies (ADVM) Chief Operating Officer Peter Soparkar reported multiple stock option adjustments on June 17, 2025, following the company's March 21, 2024 reverse stock split (10:1 ratio). All existing stock options were repriced to $10.14 per share.
Key option modifications include:
- 40,000 shares from $68.80 to $10.14, expiring 10/29/2029 (fully vested)
- 4,074 shares from $157.50 to $10.14, expiring 02/19/2030 (fully vested)
- 45,000 shares from $19.90 to $10.14, expiring 02/11/2034 (subject to vesting schedule)
The transactions involve the cancellation of existing options and simultaneous issuance of replacement options with adjusted strike prices. Total affected shares across all grants amount to 197,048. Most options maintain their original vesting schedules, with various expiration dates ranging from 2029 to 2034. This adjustment appears aimed at realigning executive incentives following the reverse stock split.
Adverum Biotechnologies (ADVM) reports changes in stock option holdings for Chief Development Officer Setareh Seyedkazemi. Following a 1:10 reverse stock split effective March 21, 2024, the company has repriced and restructured several stock option grants.
Key option modifications include:
- 42,500 shares: Exercise price reduced from $17.30 to $10.14, expiring January 2032
- 8,500 shares: Exercise price reduced from $12.90 to $10.14, expiring March 2032
- 40,000 shares: Exercise price reduced from $19.90 to $10.14, expiring February 2034
The adjustments maintain original vesting schedules: 25% first-year cliff followed by monthly vesting for most grants, with one grant vesting monthly over two years from August 2023. These modifications appear aimed at maintaining incentive value following the reverse split, with all options repriced to $10.14 per share.
Linda M. Rubinstein, Chief Financial Officer of Adverum Biotechnologies (ADVM), reported modifications to stock options following the company's reverse stock split effective March 21, 2024. The reverse split combined every ten shares into one share, with corresponding adjustments to stock options.
Key transactions on June 17, 2025:
- Cancellation and replacement of 85,000 stock options originally granted on August 3, 2023, with exercise price adjusted from $21 to $10.14
- Cancellation and replacement of 35,000 stock options originally granted on February 12, 2024, with exercise price adjusted from $19.90 to $10.14
The vesting schedules remain unchanged: the first grant vests 25% after six months with monthly vesting thereafter until August 3, 2026, while the second grant vests 25% after one year with monthly vesting until February 12, 2028, subject to continued service.
Adverum Biotechnologies (ADVM) reported changes in stock option holdings for Chief Medical Officer Rabia Gurses Ozden on June 17, 2025. The transactions involved the amendment of existing stock options following the company's March 21, 2024 reverse stock split (10:1 ratio).
Key modifications include:
- Cancellation and replacement of 8,000 fully vested options originally granted March 17, 2022, with exercise price adjusted from $13.50 to $10.14
- Cancellation and replacement of 4,000 fully vested options originally granted June 9, 2023, with exercise price adjusted from $15.60 to $10.14
These amendments represent a repricing of executive stock options to align with current market conditions, maintaining the same number of shares (adjusted for the reverse split) but at a more favorable exercise price. The total holdings after transactions amount to 12,000 directly owned stock options.
Laurent Fischer, CEO, President and Director of Adverum Biotechnologies (NASDAQ: ADVM), reported significant modifications to stock options on June 17, 2025. The transactions involved the repricing of multiple stock option grants to a new exercise price of $10.14 per share.
Key details of the option modifications:
- Total of 564,418 options were repriced across 8 different grants
- Original exercise prices ranged from $10.90 to $237.00
- All options were converted to the new strike price of $10.14
- Various vesting schedules remain unchanged, with dates ranging from 2030 to 2034
This filing follows a 1-for-10 reverse stock split effective March 21, 2024, where all share counts and exercise prices were adjusted accordingly. The repricing appears aimed at maintaining executive incentives following stock price changes, with no change to the number of underlying shares or vesting terms.
Form 4 filing reveals that Szilard Kiss, Director at Adverum Biotechnologies (ADVM), was granted stock options on June 17, 2025. Key details:
- Received 10,450 stock options to purchase common stock at an exercise price of $2.32 per share
- Options will vest on the earlier of June 17, 2026 or the 2026 annual stockholder meeting
- Options expire on June 16, 2035
- Vesting is subject to continued service and includes accelerated vesting provision upon change of control
This grant appears to be part of the company's director compensation program. The filing was submitted by attorney-in-fact Aneta Fergson on June 20, 2025.
Adverum Biotechnologies (ADVM) director James Paul Scopa received a stock option grant on June 17, 2025. The key details of this Form 4 filing include:
- Granted 10,450 stock options to purchase common stock at an exercise price of $2.32 per share
- Options will vest on the earlier of June 17, 2026 or the 2026 annual stockholder meeting
- Options expire on June 16, 2035
- Vesting is subject to continued service and includes accelerated vesting provisions in case of a change of control
This grant appears to be part of the company's regular director compensation program. The filing was signed by Aneta Fergson as attorney-in-fact on June 20, 2025.
Adverum Biotechnologies (ADVM) director Scott M. Whitcup received a stock option grant for 10,450 shares of common stock on June 17, 2025. The options were granted with an exercise price of $2.32 per share.
Key terms of the stock option grant:
- Expiration date: June 16, 2035
- Vesting schedule: Full vesting on the earlier of June 17, 2026, or the 2026 annual stockholder meeting
- Special provisions include accelerated vesting upon a change of control
- Continued service requirement through the vesting date
This Form 4 filing, submitted by attorney-in-fact Aneta Fergson on June 20, 2025, represents a standard director compensation equity grant, demonstrating ongoing alignment between board member and shareholder interests.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
